Rabbit Polyclonal TGFBR3(N-Term) Antibody

+ +

•  

   
     Anti-TGFBR3 Antibody (N-Term) at 1:2000 dilution + MCF-7 whole cell lysate Lysates/proteins at 20 µg per lane.   Secondary Goat Anti-Rabbit IgG,   (H+L),  Peroxidase conjugated at 1/10000 dilution.   Predicted band size : 93 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     P34505 staining TGFBR3 in human placenta tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed,  paraffin-embedded sections).  Tissue was fixed with formaldehyde and blocked with 3% BSA for 0. 5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6).  Samples were incubated with primary antibody (1/25) for 1 hours at 37°C.  A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.    

•  

   
     P34505 staining TGFBR3 in human testis tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed,   paraffin-embedded sections).   Tissue was fixed with formaldehyde and blocked with 3% BSA for 0.  5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6).   Samples were incubated with primary antibody (1/25) for 1 hours at 37°C.   A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.    

TGFBR3 (N-Term) antibody targets the N-terminal region of transforming growth factor-beta receptor type III (TGFBR3), a membrane-anchored proteoglycan also known as betaglycan. TGFBR3 is a co-receptor in the TGF-β signaling pathway, which regulates diverse cellular processes, including proliferation, differentiation, and apoptosis. Unlike TGFBR1 and TGFBR2. TGFBR3 lacks intrinsic kinase activity but enhances ligand binding to these signaling receptors. Its N-terminal domain is critical for ligand interaction, facilitating the presentation of TGF-β superfamily ligands (e.g., TGF-β, inhibin) to receptors, thereby modulating signal transduction. TGFBR3 also exists in a soluble form generated by proteolytic cleavage, acting as a decoy receptor to sequester ligands and fine-tune signaling.

This antibody is widely used in research to study TGFBR3 expression, localization, and function in physiological and pathological contexts. It aids in detecting full-length or truncated TGFBR3 variants via techniques like Western blotting, immunohistochemistry, or immunofluorescence. Dysregulation of TGFBR3 is implicated in cancer (e.g., reduced expression in breast or prostate tumors), fibrosis, and cardiovascular diseases, making the antibody a valuable tool for investigating TGF-β pathway mechanisms. Its specificity for the N-terminal region ensures recognition of intact receptor forms, distinguishing them from degradation products or splice variants.